Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkPractical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients with Cancer

A Narrative Review

Liquid biopsy is increasingly being used clinically in advanced lung cancer, according to this review, and ongoing research is identifying applications of circulating tumor DNA-based testing that complement tissue analysis across a wide range of clinical settings. At many stages of the patient’s oncologic journey, circulating tumor DNA technologies are demonstrating potential benefits for patients, health care practitioners, health care systems, and researchers.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form